Cariprazine and Inrebic
Determining the interaction of Cariprazine and Inrebic and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme. When cariprazine (0.5 mg/day) was coadministered with the potent CYP450 3A4 inhibitor, ketoconazole (400 mg/day), cariprazine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 3.5- and 4-fold, respectively, while Cmax and AUC of DDCAR increased by approximately 1.5-fold each. The Cmax and AUC of another active metabolite, desmethyl cariprazine (DCAR), decreased by approximately one-third. The extent to which other, less potent inhibitors of CYP450 3A4 may interact with cariprazine and its metabolites is unknown. MANAGEMENT: Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling. References "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.
Professional:MONITOR: Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme. When cariprazine (0.5 mg/day) was coadministered with the potent CYP450 3A4 inhibitor, ketoconazole (400 mg/day), cariprazine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 3.5- and 4-fold, respectively, while Cmax and AUC of DDCAR increased by approximately 1.5-fold each. The Cmax and AUC of another active metabolite, desmethyl cariprazine (DCAR), decreased by approximately one-third. The extent to which other, less potent inhibitors of CYP450 3A4 may interact with cariprazine and its metabolites is unknown.
MANAGEMENT: Caution is advised when cariprazine is prescribed with moderate CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leukopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling.
- "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc., Parsippany, NJ.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cariprazine-Inspra
- Cariprazine-Insta-Char
- Cariprazine-Insta-Glucose
- Cariprazine-Instacort
- Cariprazine-Instacort-10
- Cariprazine-Insulin
- Inrebic-Cariprazine Hydrochloride
- Inrebic-Carisoprodol
- Inrebic-Carisoprodol and Aspirin
- Inrebic-Carisoprodol, Aspirin, and Codeine
- Inrebic-Carlson D
- Inrebic-Carmol HC